Clinical test about the monitoring of the renal function disorder at the time of the cisplatin dosage by the inulin clearance measurement

Clinical test about the monitoring of the renal function disorder at the time of the cisplatin dosage by the inulin clearance measurement - Evaluation of renal function during the cisplatin administration by the inulin

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002167

Enrollment

Registered

2009-07-16

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The malignant tumor which needs the cisplatin dosage

Interventions

inulin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The eligibility criteria are as follows; (1)Histologic or cytologic confirmation of cancer (2)The patient who needs the more than 70mg/m2 cisplatin dosage(exclude tegaful gimeracil and oteracil potassium capsule) (3)The patient are expected to survive more than 3 month (4)The patient that eGFR are more than 50ml/min/1.73 at the time of an examination start (5)Written informed consent

Exclusion criteria

Exclusion criteria: The exclusion criteria are as follows; (1)The patient who uses a medicine with the antioxygenation affecting the measurement of the inulin clearance(For example, vitaminE or probucol) (2)The patient with contraindications to inulin (3)The patient with it having been administered cisplatin within the past six months (4)In addition, the patient who judged that a doctor was inappropriate

Design outcomes

Primary

Measure	Time frame
Correlation of inulin clearance and the 24 hours urine collection creatinine clearance	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026